Drug profile · INN
granisetron hydrochloride
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride (GRANISETRON HYDROCHLORIDE) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — granisetron hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
granisetron hydrochloride (GRANISETRON HYDROCHLORIDE) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 3a (5-HT3a) receptor antagonist
Primary target: 5-hydroxytryptamine receptor 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is granisetron hydrochloride?
granisetron hydrochloride (GRANISETRON HYDROCHLORIDE) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for granisetron hydrochloride?
GRANISETRON HYDROCHLORIDE is a marketed brand name for granisetron hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of granisetron hydrochloride?
granisetron hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.